These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24549681)

  • 21. Response adaptive designs with a variance-penalized criterion.
    Yi Y; Wang X
    Biom J; 2009 Oct; 51(5):763-73. PubMed ID: 19757432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling and design of cross-over trials.
    Jones B; Donev AN
    Stat Med; 1996 Jul; 15(13):1435-46. PubMed ID: 8841653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of current guidelines on the care of postherpetic neuralgia.
    Argoff CE
    Postgrad Med; 2011 Sep; 123(5):134-42. PubMed ID: 21904096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postherpetic neuralgia: treatment strategies for pain control.
    Davis TL
    Adv NPs PAs; 2012 Sep; 3(9):29-31. PubMed ID: 23002661
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pregabalin in the treatment of neuropathic pain].
    Biegstraaten M; van Schaik IN
    Ned Tijdschr Geneeskd; 2007 Jul; 151(28):1561-5. PubMed ID: 17715763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
    Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
    Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia.
    Achar A; Chakraborty PP; Bisai S; Biswas A; Guharay T
    Acta Dermatovenerol Croat; 2012; 20(2):89-94. PubMed ID: 22726281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).
    Sang CN; Sathyanarayana R; Sweeney M;
    Clin J Pain; 2013 Apr; 29(4):281-8. PubMed ID: 22801243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of clinical efficacy with amitriptyline, pregabalin, and amitriptyline plus pregabalin combination in postherpetic neuralgia.
    Achar A; Chatterjee G; Ray TG; Naskar B
    Indian J Dermatol Venereol Leprol; 2010; 76(1):63-5. PubMed ID: 20061738
    [No Abstract]   [Full Text] [Related]  

  • 31. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
    Gore M; Sadosky A; Tai KS; Stacey B
    Clin Ther; 2007 Aug; 29(8):1655-70. PubMed ID: 17919547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimize the use of minimization with unequal allocation.
    Proschan M; Brittain E; Kammerman L
    Biometrics; 2011 Sep; 67(3):1135-41. PubMed ID: 21281276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia.
    Vinik A; Emir B; Parsons B; Cheung R
    Pain Med; 2014 Apr; 15(4):661-70. PubMed ID: 24330406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal design for dose response using beta distributed responses.
    Wu Y; Fedorov VV; Propert KJ
    J Biopharm Stat; 2005; 15(5):753-71. PubMed ID: 16078383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial.
    Irving G; Jensen M; Cramer M; Wu J; Chiang YK; Tark M; Wallace M
    Clin J Pain; 2009; 25(3):185-92. PubMed ID: 19333167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomization by minimization for unbalanced treatment allocation.
    Han B; Enas NH; McEntegart D
    Stat Med; 2009 Nov; 28(27):3329-46. PubMed ID: 19739238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive allocation for binary outcomes using decreasingly informative priors.
    Sabo RT
    J Biopharm Stat; 2014; 24(3):569-78. PubMed ID: 24697793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy.
    Baron R; Mayoral V; Leijon G; Binder A; Steigerwald I; Serpell M
    Curr Med Res Opin; 2009 Jul; 25(7):1677-87. PubMed ID: 19480610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weighted re-randomization tests for minimization with unbalanced allocation.
    Han B; Yu M; McEntegart D
    Pharm Stat; 2013; 12(4):243-53. PubMed ID: 23760923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based guidance for the management of postherpetic neuralgia in primary care.
    Harden RN; Kaye AD; Kintanar T; Argoff CE
    Postgrad Med; 2013 Jul; 125(4):191-202. PubMed ID: 23933906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.